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Abstract
There is increasing evidence that clinical trial participants are uninformed about the trials in
which they participate, raising ethical concerns regarding informed consent. The aim of this
pilot study was to explore clinical trial participants’ use of consent discussions and information
sheets when considering participating in clinical trials research. A qualitative, interview-based
pilot study was designed in order to elicit, through dialogue, details of the reasons for partici-
pants’ use of, and preferences regarding, different modes of information provision. Semi-
structured interviews were undertaken with two different groups of patients who were partici-
pants in the Reinforcement of Closure of Stoma Site trial. The first group comprised newly-
consented trial participants, who had been recruited up to 72 hours before our interview; the
second group comprised patients attending a follow-up clinic 12 months after joining the trial.
Thirteen participants were recruited in total: three newly-consented patients, and ten follow-
up patients. The study found that participants’ use of consent discussions to gain information
about clinical trials was varied, and that they only minimally used information sheets after pro-
viding initial consent for the trial. Participants demonstrated varying degrees of knowledge
about the trial, with some having forgotten that they were still involved in the trial. Participants
reported a high level of trust in medical staff as a reason for not seeking more information
about the trial. Some participants reported dissatisfaction with the timing of information provi-
sion. Some were amenable to novel ways of receiving trial information, such as web-based
methods. The pilot study demonstrated the feasibility of a larger study into the provision of
information to prospective clinical trial participants. The results suggest that considering alter-
native ways of providing information and the appropriateness of existing information provision
may be acceptable to and useful for potential trial participants.
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Introduction
Clinical trials provide valuable evidence on the efficacy and effectiveness of healthcare interventions
and this evidence can inform clinical practice and health policy. Gaining properly informed consent
to participation in research is said to demonstrate respect for research participants and for their
autonomy [1–4]. While theoretical and practical objections to the use of informed consent to pre-
serve autonomy have been raised (for example, it cannot be obtained from those without capacity
to consent, and produces quandaries when applied to the vulnerable or dependent, whose consent
may not be valid if they feel coerced [5]), the process nevertheless remains a legal prerequisite for
the inclusion of humans as participants in most forms of research. The Nuremberg Code empha-
sised participants’ ‘sufficient knowledge and comprehension of the elements of the subject matter
involved’ as a necessary condition for consent [6]. More recently, the importance of information in
consent has been codified in the Declaration of Helsinki [7], the EU Clinical Trials Directive (2001/
20/EC) [8], and in the UK, the Medicines for Human Use (Clinical Trials) Regulation 2004 [9].
Participant information sheets (PIS) are routinely provided as a basis for discussion between the
potential research participant and the healthcare/research team about taking part. PIS are, however,
becoming increasingly long, which may deter some potential research participants, thereby limiting
the generalizability of research results. Furthermore, previous research has shown that some partici-
pants are willing to participate in research despite understanding little or none of the information
provided [10,11]. It is therefore unsurprising that analysis of the consent process for research has
highlighted many studies whose participants had incomplete or inaccurate understanding of the tri-
als in which they were participating [12–17]. Studies have concluded that research participants’
recall of information about the trial on which they are enrolled is low, and they are often unaware
of the aim of the trial and the fact that their participation is voluntary [18,19].
In this paper, we report the results of pilot work aimed at determining: 1) the extent to
which potential participants, at the time of giving consent, rely on information sheets and/or
consent discussions to inform their decision to participate; 2) the extent to which participants
consult their information sheet at other points during a trial, and for what purposes. This pilot
study adds to the existing body of work exploring participants’ experience of the consent pro-
cess and their use of opportunities to get trial information. In particular, this study focused on
participants’ use of consent discussions and written information resources throughout the pro-
cess of being trial participants. This study is a precursor to future work that will investigate bet-
ter ways of providing information to participants.
Methods
A qualitative pilot study was designed to explore whether and to what extent participants used
written information and/or consent discussions to inform their decisions. This was intended
to determine the feasibility of a larger study looking at ways to improve the quality of the infor-
mation-sharing part of the consent process. By “consent discussion” we mean the meeting dur-
ing which the research participant discussed the research with a member of the research team,
had an opportunity to ask questions, decided to take part, and recorded formal consent, usu-
ally in writing, and witnessed by the team member [20]. According to Good Clinical Practice
(GCP) guidelines, the consent discussion should recap the main points in the information
sheet, which is typically provided ahead of time. If potential participants are not reading the
information sheets before the consent discussion, the interview becomes a crucial means by
which information is provided prior to securing consent to participate. A qualitative, inter-
view-based method was appropriate to meet the aims of the study, given that we hoped to
elicit, through dialogue, details of the reasons and rationales behind participants’ use of, and
preferences regarding, different modes of information provision.
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The PIS is intended not just to inform a consent decision, it is also a point of reference for
information that a participant might want during a trial. To understand how the PIS was being
used in both contexts, we wanted to interview people who had recently given consent to partic-
ipate and those who had been in a trial for several months.
Clinical trials units at the University of Birmingham were contacted to identify potential tri-
als in which this qualitative study could be embedded. Our inclusion and exclusion criteria,
based on our aims, were as follows:
Inclusion criteria–stage one
Anyone over the age of 18, with capacity to consent, who had agreed to participate in a clinical
trial within 72 hours prior to the interview.
Inclusion criteria–stage two
Anyone over the age of 18, with capacity to consent, who was currently participating in a trial
and had been enrolled on that trial for at least a month at the time of interview.
Exclusion criteria–both stages
Anyone unwilling to participate.
Anyone who lacked capacity to consent
Sampling
Sampling of study participants was constrained by the need to identify an ongoing clinical trial
being conducted by researchers who were: willing to allow us to embed our study into their
trial, including seeking an amendment to their research ethics approval, and speak to their par-
ticipants; recruiting participants at a sufficient rate for us to gather our data within the
6-month study period; recruiting participants in such a way that it would not be unduly bur-
densome to recruit them to a further study shortly afterwards.
The Reinforcement of Closure of Stoma Site (ROCSS) trial [21] met these criteria. Patients
undergoing stoma reversal surgery and who agreed to participant in ROCSS were randomised
either to receive a biological mesh to strengthen the stoma site or to receive the standard avail-
able therapy (i.e. no such mesh). Participation in this trial was not regarded as posing a high
risk; participants were undergoing surgery anyway. Nevertheless, the inclusion of the mesh
intervention was not entirely risk free, so a reasonably large amount of information provision
for participants might be expected.
Convenience sampling was used to select participants in the ROCSS trial at one of its sites.
Participants were approached at their regular clinical appointments by a member of the
ROCSS team, and asked for their permission for a researcher to speak to them. No record was
kept of participants who refused this permission. ROCSS participants who expressed an inter-
est in participating in our study were met individually by SJ. SJ explained the pilot study infor-
mation sheet to them, and those who gave consent recorded this on a consent form.
Ethics approval and consent to participate
Our pilot study protocol, information sheets, and consent forms were submitted as an amend-
ment to the ROCSS trial (favourable opinion reference 12/WM/0187 –Coventry and Warwick-
shire Research Ethics Committee). Appropriate local Research and Development (R&D)
permission was gained to access participants at the Queen Elizabeth Hospital, Birmingham.
All interviewees gave written consent to participate.
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Interviews
Research team and reflexivity. SJ conducted the interviews from May to July 2014, in a
private room in the hospital where the participant was having their clinical visit. There was no
relationship between the research team and the participants prior to commencing the study,
and participants were told that the interviewer was a researcher from a nearby university. HD
and MC had already published work on problems with the informed consent process [11,15],
so confirmation bias may have influenced their interpretation of the data.
Study design. The interviews were semi-structured, making use of a topic guide (S1
Appendix) with various prompts [22], which ensured that data was gathered consistently. Ques-
tions on the topic guide asked about: which part(s) of the research the participants found strik-
ing or influenced their decision whether to participate; what the positives and negatives about
participating would be; which questions they asked in the consent discussions; where they kept
and how much they referred back to written information (the information sheet) about the
trial; what kind of information they would refer back to and what kind of information they
thought others might refer back to in the information sheet; and, what they thought about dif-
ferent modes of information provision, including an electronic expanding information sheet.
The questions were open-ended, however, so that participants had the opportunity to raise and
discuss issues that were important or interesting to them [23]. Part of the strategy for determin-
ing participants’ use of information was to attempt to establish how much they knew about the
trial in which they were participating. Rather than gathering the data through the use of direct
testing of knowledge, questions were posed in an indirect way, in order to mitigate the risk of
participants feeling “tested” on their understanding or embarrassed if they were unable to pro-
vide answers. This ethical decision led us to design a topic guide with open questions, bringing
our interview approach slightly further towards a narrative interview [24,25], as we asked partic-
ipants to provide us with a broader account of their experience of the consent process.
Analysis
Data from the interviews were transcribed verbatim from the audio recordings. SJ read the
transcripts several times and then coded them for relevant themes. Coding was undertaken by
a single researcher (SJ). HD read all of the interview transcripts, and themes were reviewed by
experts in ethics and trials (HD and MC). The analysis followed a process of iterative content
analysis, using constant comparison methods [26], where codes were refined and grouped into
categories as the coding process progressed. Cases that were inductively inconsistent with the
emerging themes were identified and given special consideration, in line with the process of
deviant case analysis outlined by Silverman [27]. Meetings were held between the authors to
discuss and review the identified themes.
Results
Thirteen participants were recruited to our study from the ROCCS trial (Table 1).
Table 1. Data collection phases and participants.
Stage Type Participant Gender
1 Interviews lasted 7–20 mins (mean
12 mins)
Newly-consented ROCSS participants (n = 3) 2 male; 1
female
2 Interviews lasted 7–23 mins (mean
12 mins)
ROCSS participants at a 12-month follow-up
appointment (n = 10)
8 male; 2
female
https://doi.org/10.1371/journal.pone.0234388.t001
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Analysis of results suggested six themes. Themes one to three relate to our first two research
questions exploring participants’ use of information sources and the effect this had on their
knowledge of the trial. Theme four explores a possible explanation for their limited use of this
information, as participants provided reasons for their attitudes in a way that was philosophi-
cally interesting, although somewhat unexpected. Finally, themes five and six summarise the
suggestions that participants had for improving the process.
Theme one: Varied and limited use of consent discussions
One of the study’s aims was to establish whether and to what extent participants made use of
participant information sheets or of information provided in the consent discussions when
deciding whether to participate in trials. The newly-consented participants were specifically
asked whether they had asked questions in their consent discussions. While follow-up partici-
pants were not asked about this specifically, a minority of them talked about the questions they
had asked at the time of consent. Across both groups, most of those who commented reported
that they did ask questions of the research team (though those who did not ask questions in
the follow-up group may have been less likely to bring up the subject):
I just asked the doctor next door whether I was okay to, to go abroad again. . . [I’m] just wor-
ried about the insurance part, if anything happened, or if I was ill’ (FU5—these codes are the
participant identifiers–“FU” signifies “follow-up”, a stage two participant, and “NC” means
“newly-consented”, a stage one participant).
One participant said that they wanted to benefit medical science, and therefore did not
want to know information about the disadvantages of participating in the trial in case this
deterred them from participating:
[I]f I thought there were downsides, I wouldn’t agree, because if you’re going to agree to some-
thing, you need to walk in looking at the positives, if you look at the negatives, you might not
agree to participate, so I didn’t give that much attention, I didn’t ask (NC2).
Use of consent discussions was therefore varied, though no participant reported asking
more than one question, and two (one NC and one FU) reported asking nothing.
Theme two: Minimal ongoing use of information sheets
The study also aimed to ascertain the extent to which participants used the information sheets
throughout the trial. Only the FU participants were asked directly about this (NC participants
were interviewed shortly after their consent discussion, so this was less likely to be applicable
to them). Participants’ use of the information sheet over the course of the trial varied. Some
reported not having looked at it at all:
I haven’t looked at it since (FU6).
[W]e’d completely forgotten all about [the trial] (FU7 –referring to himself and his wife).
When participants elaborated on what did or would lead them to revisit their information
sheet, they commonly reported that they may revisit information about the trial if they experi-
enced adverse events that they thought were relevant to their condition or surgery. Some of
these participants had experienced such adverse events, and had subsequently consulted the
trial information:
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I had a wound that’s not healing properly and it said see the doctors but they said it would
heal, so I was really just that once, looking to see, for the information (FU8).
Others had neither experienced such events nor revisited the information:
I haven’t been back to the information since the procedure, mainly because there’s been no
issues (FU10).
Others spoke more abstractly and did not say whether they had experienced such events
themselves, but also reported that these events might be key in determining whether they
would revisit the trial information:
I think where it gets important is where there is an incident, whatever it is that might be
(FU9).
Overall, the use of information sheets amongst participants as the ROCSS trial went on was
minimal. Most FU participants ignored the information sheet unless they experienced health issues
that they felt may have been related to the trial or the existing condition to which the trial related.
Theme three: Awareness of the trial
As the pilot study also aimed to gain an understanding of participants’ awareness of the trial in
which they were participating, the topic guide included questions that would require partici-
pants to demonstrate at least a basic knowledge of the trial. All three of the NC participants
were able to describe the basics of the ROCSS trial:
[T]hey said that if I consented to do the trial, erm, it was to something like a mesh, so that
you, if you’re at risk of having a hernia, the mesh would potentially prevent that. It was a ran-
dom test, and even if you agree to be on the, er, the trial, it doesn’t necessarily mean that you
will have had the procedure done (NC3).
Knowledge amongst the FU participants, however, was highly varied. Some, like the NC
participants, were able to describe the basics of the trial, with some being able to describe the
different trial arms:
[T]hey said that my wall would be weakened by what they had to do inside my stomach when
they done the operation, so by putting this mesh in, it was going to like, help the strength of it.
I couldn’t control whether the surgeon put it in or didn’t put it in (FU3)
One of the participants reported having forgotten about being in the trial until the appoint-
ment letter had arrived, and a small number of participants seemed unable to describe any ele-
ment of the trial.
You see, it’d been over a year, and maybe a year is too long [hmm]. You see, I—well we’d–as I
say–we’d completely forgotten all about it (FU7).
If I had [the information sheet] a year ago, I probably did scan through it erm, but err that’s
as much as I can tell you (FU9).
In summary, while some of the participants had a good knowledge of the basics of the trial,
others were very unaware of what the trial was about, or even that they were still part of it.
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Theme four: Participants trusted the medical staff
Many of the participants related their lack of interest in information about the trial to their
trust in doctors and medical staff:
I’m just the guinea pig. You do the paperwork and you follow it up and that’s your business.
I’ll be there for you to practice on, or whatever, but I’m not interested in paperwork at all
[. . .]. I’m happy to be the guinea pig, but I’m not concerned what comes out of it. I’m not
gonna go out and get The Lancet and see what studies, you know [right], are on trial at the
moment. So, you know, I’m willing to help in any capacity, but I don’t look at it (FU2).
I’m sure as it went on, I’d get told all the little details–throughout all the appointments, and
just going to clinic appointments and checkups and everything [. . ..] I just, kind of, go with
what the doctors tell me, erm, because I’m sure they’re very good at their job and don’t do any-
thing wrong–(FU1).
FU2’s use of “you” may betray this participant’s mistaken belief that the interviewer for the
sub-study was involved in the ROCSS parent trial.
FU1 seemed confident that their doctors would act appropriately, but they also seemed not
to appreciate the difference between interventions relating to their treatment and interventions
relating to the trial.
In one case, a participant’s trust in the medical team was such that they suggested that the
trial be presented to patients as a routine part of the operation, which would circumvent gain-
ing consent:
I would just say, ‘you can just—it’s part of the operation [okay], part of the routine operation,
and that’s what we do, that’s what we’re gonna do, because it’s not gonna harm you, but it
could benefit you’ [. . .]. Obviously, I wouldn’t override someone that, I don’t know, you know
what I mean, he obviously knows more than me (NC1).
This participant seemed to expect that the research intervention would be beneficial to
patients, but it nevertheless provides an interesting (although outlying in terms of this
dataset) view about consent being unnecessary. However, this participant thought consent
was unnecessary on the basis that participation in the trial would cause them no harm.
They appeared not to be aware that there were risks involved in participating (e.g. reduced
prophylactic prevention of herniation), even though these were clearly outlined in the
PIS.
To summarise this section, many participants seemed to trust that staff would automati-
cally provide them with any information that was important to them personally. They
therefore did not feel the need to be proactive about informing themselves, or find it neces-
sary to read the information sheet, which would not provide such personally-tailored
information.
Theme five: Participants wanted more time to read information
Participants’ views about when information should be given about trials were also varied. This
question was included as a prompt on the topic guide, so participants were asked directly
about this. Some of the participants did not receive the written trial information until the day
of their surgery, and while it should be noted that this was consistent with the trial’s protocol,
some of these participant criticised this timing:
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[T]o be given that information a little bit in advance, just gives you that extra kind of breath-
ing room that extra pause to really take the time to think and make a more informed decision
for yourself (FU10).
[I]f I had had longer to think about it, it would have been better (FU3).
An alternative view, however, voiced by one participant, was that this timing could be a pos-
itive thing from the perspective of better ensuring that participants would actually read the
information:
[B]ecause of err, that particular environment where you’re locked into it and you are waiting
to be called for your operation, you’re, it’s nice to have something to read because it gives you
something to get involved with, so yes, I think it is good and useful to have in, at that point.
Because if you handed it to me in the street or something, I would have gone hmmm, and
shoved it in my bag and not, or like when you get so much information in the post, you think
oh, and you chuck it, so it was a different way of receiving but also because you were a captive
audience–(NC2).
In summary, participants tended to emphasise the importance of having sufficient time to
read the trial information, with one notable and interesting exception regarding a possible
more strategic approach to the timing of information provision.
Theme six: Participants wanted varied modes of provision
Participants were asked directly about different modes of information provision. They were
invited to consider their preferences regarding written paper information, video information
on DVDs or in YouTube clips, and an electronic expanding information sheet [15].
A common point raised by the study participants was a concern over newer technologies
being used to convey information, as not everyone would have access to them:
I don’t have a computer or smart phone or such technology (FU4).
On the other hand, some participants were more enthusiastic about the idea of non-written
forms of receiving trial information:
A DVD for me. I don’t do reading (FU2).
Other participants interpreted the question less subjectively and, acknowledging that differ-
ent potential participants may wish to receive the information in different ways, suggested that
a variety of different modes be made available to participants:
A little package saying you can get it, you can review it this way, or you can have a DVD, or
you can read about it (NC1).
[P]eople learn in different ways and take information differently so it’s just best to cover all
bases, then no one can say that they haven’t been well informed at any stage (FU10).
To summarise, some participants considered that different modes of receiving information
would work better for different people, and individual participants confirmed this by discuss-
ing their own preferences.
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Discussion
Implications for further research
This study has provided valuable pilot data on the consent process for a surgical trial and the
use of PIS and consent discussions. Participants reported varying degrees of knowledge about
the trial and varying use of the trial information sheet over the course of the trial. Our results
also show that there may be some demand for more multi-faceted means of information provi-
sion rather than reliance on the information sheet and consent discussions.
The main operational challenge in this study was identifying a suitable trial in which to
embed. Working in conjunction with a trial from the outset would streamline the approvals
process and provide greater opportunities to sample participants at different stages of the trial.
Discussion of pilot study results
Trial knowledge and use of information and consent discussions. Participants some-
times reported ignorance of the trial, and this gap in the consent process may mean that partic-
ipants’ autonomy is being compromised, as participants are insufficiently informed for their
consent to be valid. Additional measures may therefore be required to ensure that participants
are given information that they understand. Further thought may also be needed on the ques-
tion of how long participants should be expected to retain information, and for how long their
continued participation in a trial can be considered autonomous if they begin to forget key
details of the trial. Moving to a model of continuous consent, where consent is reaffirmed at
stages throughout the trial, would be in line with proposals to use a process-based rather than
event-based model of consent [28–29].
Conversely, if participants are unconcerned about trial information yet still happy to partic-
ipate, a good alternative might be a reframing of the recruitment process to better fit with
these desires. If, as indicated in this pilot study, participants’ trust of healthcare practitioners is
central to their decision-making, it may be worth exploring the introduction of trust and trust-
worthiness as operative concepts in place of autonomy in these settings. If research partici-
pants are happy to act on the basis that they trust the practitioner who is recruiting them to the
study, then perhaps the focus should move towards ensuring that trials are safe and that staff
involved with them are acting with integrity, than on providing information to participants
who may not really want that information. Such a model would be sympathetic to the pro-
posal, suggested by some authors, to recognise the centrality of trust in the patient-doctor rela-
tionship, and move the focus away from individualistic accounts of patient autonomy that
overemphasise patient choice and underplay the role of doctors (and the wider medical and
research community) in ensuring that patients and research participants make choices that are
best for them [30].
Our participants’ recollections of their consent discussions is consistent with previous stud-
ies’ findings showing problems with information sheets, includinglimited reading of the PIS,
and consequent general limited understanding of the trial itself [10–19]. This may be partly
because they assume that the trial will benefit them or others, and that no harm will come to
them by participating (the related notion of trusting the doctors and medical staffis discussed
in further detail below). The ROCSS trial was not risk-free, but it was a relatively low risk trial.
It may be reasonable to suppose that greater potential risks may have prompted participants to
pay more attention to the information provided, and more of a reason for researchers to
ensure that participants understood this regardless of any apparent lack of interest from them.
Further research into participant information in different risk contexts would therefore be
useful.
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Timing of information. Respect for participant autonomy is frequently cited as the rea-
son for ensuring that participants with capacity to do so give informed and voluntary consent.
It seems self-evident that good conditions for ensuring autonomous, informed choice are
those in which the participant is given sufficient time to become acquainted with and consider
the trial information. If this is true, it might follow that the more time a participant is given to
read the information, the better (within limits–they may forget information if too much time
passes). This may provide another reason for some participants’ lack of information-seeking
about the trial, as they may not have had sufficient time to formulate questions.
Participant NC2, on the other hand, was glad to receive information on the day of surgery.
While not representative of the study population as a whole, this view warrants further atten-
tion. It is often thought that being given information close to the time when a decision is
required is an obstacle to considered decision-making. This assumption may be worth explor-
ing in future research. A further, larger consultation with patients and the public may help to
identify the best time to provide trial information to potential participants, and this timing
could then be made explicit in trial protocols and ethics applications. If we wish to maintain a
model of recruitment to trials that focuses on autonomy, this may best be served where partici-
pants are reminded periodically about their ongoing trial participation. A truly process-based
model of consent must take the suggestion of these reminders seriously. These reminders,
however, may lead to a higher attrition rate, and further compound the biases introduced by
the requirement only to use consenting participants. These are considerations that would need
to be weighed against the better preservation of participant autonomy.
Trust in medical staff. The participants showed a high level of trust in the medical staff,
though in some cases they did not seem able to distinguish between medical staff involved
directly in their care and those involved as reseachers in the ROCSS trial. This may have been
a product of incorporating trial-related interventions into the usual care pathway as much as
possible, for example by arranging ROCSS-related follow-up appointments to take place at
normal follow-up clinics that patients would attend irrespective of their participation in
ROCSS. It is somewhat paradoxical that a measure designed to minimise the inconvenience to
trial participants may actually compromise their knowledge and level of understanding and
information about their research participation.
In spite of this confusion, many participants seemed to assume that the trial would be posi-
tive in some way and would not disadvantage them. Many suggested that a major factor in
their decision to look at the information sheet during the trial would be whether or not they
experienced any health issues that could be related to the condition leading them to be in the
trial (in this case, the stoma reversal operation). It is therefore perhaps unsurprising that many
participants did not look at the trial information–many of them were just happy to think that
they were helping. This may also help to explain why some of the follow-up participants were
unable to describe even the basic elements of the trial. A similar study in a higher risk trial may
yield different results. The participants’ level of trust may also vary from trial to trial depending
on the amount of related contact with the staff their condition has required.
Another paradox is illuminated by the participant who argued that potential trial partici-
pants do not need information about trials that will not harm them. This participant’s trust in
the trial team may have been somewhat misplaced, given that there were risks associated with
participating in the ROCSS trial, meaning that freedom from harm was not guaranteed. It may
have been interesting to probe this further with the participant to verify their awareness of
these risks, but asking the participant about these risks may have scared them, or made them
feel embarrassed about agreeing to participate without knowing about them. This is therefore
an area in which the conduct of the research itself generated ethical issues.
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Addressing the problem. The fact that participants did not ask questions at the time of
enrolment, and that they were sometimes unaware of their participation in clinical trials after
a year, suggests either that there is something wrong with the current means by which infor-
mation is provided to potential trial participants, or that the paradigm that insists that this
information is offered is misguided. A dramatic way to resolve this problem would be to
acknowledge that potential participants are often uninterested in extensive study information,
and accept their trust in the medical profession by allowing them to participate without under-
going the rigorous informed consent process that is insisted on today. Participants would then
receive information only on request. Removing this hurdle would allow more participants to
realise the social goods of participating in research [30–31].
This trust system could be bolstered by the addition of measures that would make the medi-
cal and research community more trustworthy, such as greater monitoring of the process of
recruitment to trials, for example by having an extra person in the room when participants are
enrolled who can ensure that the process is noncoercive.
Stopping short of such a paradigm shift, if we wish to keep using information sheets and
recording consent formally, there are two tangible improvements that may address the prob-
lem of participants’ poor understanding and retention. The first is through the provision of
information using a web-based expanding information sheet, which facilitates reading by
introducing information in varying degrees of complexity, and helps the user to select the
amount of information they want to read [15]. Second, given the dubiousness of the assump-
tion that a one-off consent process protects participants’ autonomy, a process of refreshing
participants’ consent at intervals may better achieve this end [32]. Making alterations to both
the mode and the timing of information provided to participants may be necessary to avoid
the pitfall, encountered by many authors, of information provision becoming an empty “medi-
cal Miranda” ritual that does not fulfil its intended function [13, 29, 33].
Our pilot work suggests that online expanding information might be acceptable to potential
participants. Some of our participants expressed reluctance to obtain information by reading a
conventional information sheet, and others thought that different mediums for providing
information could be an advantage. Electronic expanding information provision can accom-
modate pictures and links to videos in which the trial (or parts of it) is (or are) explained ver-
bally, with pictures, cartoons, other means of communication, or some combination of
different media. It also responds to an increasing reliance on and acceptability of electronic
forms of communication accessed via mobile devices. We do not expect this to be a panacea,
but it may improve the situation by broadening the methods of communication to potential
participants, whilst also making the process both more interesting and more convenient.
If those conducting consent discussions are placing more emphasis on the consent discus-
sion over PIS, then ethics committees should consider mirroring this emphasis. This could be
achieved quite easily, by putting information into a standardised script that is read to or dis-
cussed with all potential participants. This script could also undergo review by the research
ethics committee in the same way a PIS does currently.
Study strengths and limitations
Embedding our pilot into an active trial means that our findings have greater validity than if
we had developed hypothetical scenarios for participants to consider. In terms of the number
of participants, the time-consuming nature of identifying a suitable and willing trial delayed
the project to the extent that we under-recruited–further recruitment might have been possi-
ble, but stopped when the project ran out of time, before the point of theoretical saturation.
This delay, in combination with the convenience sampling approach necessitated by the
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conditions under which the trial was undertaken, means that the ‘qualitative power’ [34] of the
study (the usefulness of the study’s data relevant to sampling methods and sample size) may be
low. A better approach in future would be to approach trial teams while their protocols are still
being written, to avoid the need to return to the ethics committee for an amendment, and to
allow for a more scientifically robust sampling method. The study nevertheless fulfilled its
aims as a pilot study in demonstrating that gathering further data from patients about their use
of information, particularly in trials where the risks are different, would be a useful future
endeavour.
The ethics committee who reviewed the amendment to the ROCSS protocol recommended
that we provided written information sheets and record written consent for our participants.
This would not have been required for an audit of the ROCSS consent process. We suspect
that this process led to some confusion about the relationship between the ROCSS parent
study and our sub-study even though we attempted to mitigate this risk with careful explana-
tion to our participants, both in the information sheets themselves, and in the process of gain-
ing their consent to participate in the sub-study. Nevertheless, if participants were confused
about the questions they were being asked in the interviews, this will have affected the study’s
results. We were highly conscious that our own study should not deflect attention away from
either the patients’ decision to have surgery, or the decision to participate on the ROCSS study.
However, work to improve the provision of information to research participants is important
and cannot all be conducted hypothetically or with user groups. Consideration needs to be
given to how best to gather “real-time” information from participants that is not unduly bur-
densome, is not a distraction, and provides safeguards that are proportionate to the risks of
participation. Data from a pilot of this size should be interpreted with caution, and the passage
of time since the data were collected might make some of the participants’ comments out of
date (for example, regarding the usefulness of DVD information and greater penetration of the
smartphone market). Nevertheless, the study highlights interesting and useful themes.
Conclusions
Summary
• A larger study of a similar nature would be feasible, but embedding the larger study
into a trial at a much earlier stage would be more efficient and produce better results.
• Participants reported varying degrees of trial knowledge, and varying use of both con-
sent interviews and trial information over the course of the trial.
• Participants placed a high degree of trust in medical staff. It may be worth exploring
the introduction of trust as an operative concept in place of autonomy in these settings.
Further research to establish any factors affecting this level of trust would be useful.
• Future potential trial participants may benefit from different methods of receiving
information, including different approaches to timing.
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Our pilot study corroborates previous work suggesting that trial participants’ use of different
means of information provision is highly varied, with some participants reporting having
asked no questions in the consent discussion, and some reporting limited or no use of the
paper information sheet provided to them. Likely as a consequence of this, participants were
sometimes unaware of the nature of trials in which they were participating, or even whether
they were participating at all. Our findings suggest that alternative methods, including non-
written methods of trial information provision may be at least as acceptable, and may improve
participants’ understanding of trials, protecting their autonomy with regard to making poten-
tially risky decisions.
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